Adaptive licensing could ‘transform industry’
December 17, 2014Research and Development, Sales and Marketing Clinical Pharmacology & Therapeutics, EFPIA, EMA, MHRA, adaptive licesning
Drug regulators should switch to adaptive pathways as the preferred approach to bringing future new medicines to patients, according to …
GSK Ebola vaccine gets EU support
December 17, 2014Research and Development, Sales and Marketing EC, EU, Ebola, Europe, GSK, Merck, Takeda, Vaccine, WHO, johnson
A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …
Cell Therapy Catapult to build £55 million bioscience campus
December 17, 2014Research and Development, Sales and Marketing Cell Therapy Catapult, UK, bioscience, research, stevenage
UK firm The Cell Therapy Catapult has chosen to build a £55 million state-of-the-art cell therapy manufacturing centre in Stevenage. …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
Gilead secures senior head from Genentech
December 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Gilead, Philippe Bishop
Dr Philippe Bishop is joining the California-based biopharma firm Gilead from Genentech to be the company’s senior vice president of …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
Novartis hormone disorder drug approved in US
December 16, 2014Sales and Marketing FDA, Lar, Signifor, acromegaly, cushing, hormone, pasireotide
The FDA has approved Novartis’ Signifor (pasireotide) for the treatment of a rare and life-threatening hormonal disorder. The US Food …
Pfizer buys OPKO growth hormone drug
December 16, 2014Research and Development, Sales and Marketing Pfizer, ghd, growth, hGH-CTP, hormone, merger, opko
Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
AstraZeneca closing US manufacturing unit
December 16, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, Pulmicort, malloy, short haircuts, westboro
AstraZeneca is closing its Otis Street manufacturing plant next year that has been in operation for 33 years, and the …
Riemser Pharma recruits former GSK head
December 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, riemser pharma, thomas werner
Riemser Pharma in Germany has appointed Dr Thomas Werner to its advisory board. The former head of GlaxoSmithKline and Bristol-Myers …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
Abbott buys Russian firm Veropharm
December 15, 2014Manufacturing and Production, Sales and Marketing Abbott, Fresenius, cfr pharma, petrovax, sistema, veropharm, zenitco
Abbott has completed its purchase of Russia-based Veropharm in a $305 million deal as it looks to firmly establish itself …
Mixed bag for Novartis and Astellas in breast cancer
December 15, 2014Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus
Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
Vermillion takes on two senior heads
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing david schreiber, vermillion, veronica jordan
US drug development firm Vermillion has appointed Veronica Jordan and David Schreiber to the company’s board of directors. Dr Veronica …
Pharma to lose $69 billion in five years as patents expire
December 12, 2014Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma
Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
